FibroGen Inc (FGEN) Holdings Lifted by Los Angeles Capital Management & Equity Research Inc.

Los Angeles Capital Management & Equity Research Inc. raised its position in FibroGen Inc (NASDAQ:FGEN) by 3.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 31,362 shares of the biopharmaceutical company’s stock after buying an additional 1,085 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in FibroGen were worth $1,705,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in FGEN. Lindbrook Capital LLC grew its stake in FibroGen by 150.0% during the 1st quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Meeder Asset Management Inc. grew its stake in FibroGen by 622.4% during the 4th quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 529 shares in the last quarter. Intercontinental Wealth Advisors LLC acquired a new position in FibroGen in the 4th quarter valued at about $37,000. Flinton Capital Management LLC acquired a new position in FibroGen in the 4th quarter valued at about $44,000. Finally, Neuburgh Advisers LLC acquired a new position in FibroGen in the 4th quarter valued at about $53,000. 66.67% of the stock is owned by institutional investors.

Several equities analysts have weighed in on FGEN shares. Piper Jaffray Companies started coverage on shares of FibroGen in a report on Friday, April 12th. They issued a “neutral” rating and a $65.00 target price on the stock. Stifel Nicolaus started coverage on shares of FibroGen in a report on Monday, February 11th. They issued a “buy” rating and a $71.00 target price on the stock. BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 10th. ValuEngine lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 14th. Finally, Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a report on Tuesday, January 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. FibroGen has an average rating of “Buy” and a consensus price target of $70.00.

In other news, CEO Thomas B. Neff sold 48,180 shares of the company’s stock in a transaction that occurred on Friday, February 8th. The shares were sold at an average price of $56.47, for a total value of $2,720,724.60. Following the transaction, the chief executive officer now directly owns 2,680,346 shares in the company, valued at approximately $151,359,138.62. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director James A. Schoeneck sold 2,000 shares of the stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $57.17, for a total transaction of $114,340.00. Following the sale, the director now owns 29,700 shares in the company, valued at $1,697,949. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 268,721 shares of company stock worth $14,863,268. Company insiders own 8.96% of the company’s stock.

Shares of FGEN stock opened at $45.92 on Wednesday. The company has a current ratio of 7.75, a quick ratio of 7.75 and a debt-to-equity ratio of 0.18. FibroGen Inc has a one year low of $37.27 and a one year high of $68.55. The company has a market capitalization of $4.14 billion, a PE ratio of -44.58 and a beta of 1.60.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.02 by $0.21. FibroGen had a negative net margin of 40.58% and a negative return on equity of 16.84%. The firm had revenue of $108.05 million for the quarter, compared to analyst estimates of $72.15 million. During the same period in the prior year, the business posted ($0.27) EPS. The business’s revenue for the quarter was up 251.5% compared to the same quarter last year. Equities analysts expect that FibroGen Inc will post -0.97 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “FibroGen Inc (FGEN) Holdings Lifted by Los Angeles Capital Management & Equity Research Inc.” was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/08/fibrogen-inc-fgen-holdings-lifted-by-los-angeles-capital-management-equity-research-inc.html.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: What is a recession?

Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.